

REGENERON PHARMACEUTICALS INC

Form 8-K

May 05, 2006

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): May 4, 2006 (May 3, 2006)

**REGENERON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)**

New York (State or other jurisdiction of incorporation)	000-19034 (Commission File Number)	133444607 (I.R.S. Employer Identification Number)
777 Old Saw Mill River Road, Tarrytown, New York (Address of principal executive offices)	(914) 347-7000 (Registrant's telephone number, including area code)	10591-6707 (Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition

Item 9.01 Financial Statements and Exhibits

Exhibit Index

EX-99.A: PRESS RELEASE

Table of Contents

Item 2.02 Results of Operations and Financial Condition

On May 3, 2006, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and three months ended March 31, 2006. The press release is being furnished to the Securities and Exchange Commission pursuant to Item 2.02 of Form 8-K and is attached hereto as Exhibit 99(a).

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99(a) Press Release of Regeneron Pharmaceuticals, Inc. dated May 3, 2006.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS,
INC.

Dated: May 4, 2006

By: /s/ Stuart Kolinski

Stuart Kolinski
Vice President and General
Counsel

Table of Contents

Exhibit Index

Number Description

99(a) Press Release of Regeneron Pharmaceuticals, Inc. dated May 3, 2006.

3